Skip to content
Dr Zarir F. Udwadia
  • Home
  • About
    • Achievements
    • Publications
    • Highlights
    • News & Updates
  • Gallery
  • Patient Information
    • Asthma
    • COPD/Emphysema
    • Bronchiectasis
    • Interstitial Lung Disease
    • Idiopathic Pulmonary Fibrosis
    • Sarcoidosis
    • Tuberculosis
    • Multi-drug resistant tuberculosis
    • Obstructive Sleep Apnea Syndrome
  • Contact
  • Corona Updates
Menu Close
  • Home
  • About
    • Achievements
    • Publications
    • Highlights
    • News & Updates
  • Gallery
  • Patient Information
    • Asthma
    • COPD/Emphysema
    • Bronchiectasis
    • Interstitial Lung Disease
    • Idiopathic Pulmonary Fibrosis
    • Sarcoidosis
    • Tuberculosis
    • Multi-drug resistant tuberculosis
    • Obstructive Sleep Apnea Syndrome
  • Contact
  • Corona Updates

Publication

  1. Home>
  2. Publication>
  3. Page 6
  • Post author:plus91
  • Post published:April 5, 2015
  • Post category:Publication
  • Post comments:0 Comments

AbstractEosinophilic granulomatosis with polyangitis (EGPA; earlier called Churg-Strauss syndrome) is a small-vessel necrotising vasculitis typically characterised by asthma, lung infiltrates, extra-vascular necrotising granulomas and hyper-eosinophilia. Cardiac disease is…

Continue ReadingEosinophilic Granulomatosis with Polyangitis Presenting as Cardiac Tamponade.
  • Post author:plus91
  • Post published:March 23, 2015
  • Post category:Publication
  • Post comments:0 Comments

Go to Publication

Continue ReadingTuberculosis in India.
  • Post author:plus91
  • Post published:March 2, 2015
  • Post category:Publication
  • Post comments:0 Comments

Abstract OBJECTIVE: To correlate gyrA mutations found on the Genotype MTBDRsl assay in Mycobacterium tuberculosis (MTB) isolates with Minimum Inhibitory Concentrations (MICs) to the fluoroquinolones compounds ofloxacin (OFX)…

Continue ReadingCorrelating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay.
  • Post author:plus91
  • Post published:February 17, 2015
  • Post category:Publication
  • Post comments:0 Comments

AbstractPirfenidone is an anti-fibrotic drug which has been approved for the management of patients with Idiopathic Pulmonary Fibrosis (IPF). However, its role in interstitial lung disease (ILD) due…

Continue ReadingImproved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis.
  • Post author:plus91
  • Post published:January 12, 2015
  • Post category:Publication
  • Post comments:0 Comments

Go to Publication

Continue ReadingResponse to Dr Daley’s article: Do not ignore the private sector.
  • Post author:plus91
  • Post published:November 18, 2014
  • Post category:Publication
  • Post comments:0 Comments

AbstractDrug-resistant tuberculosis (DR-TB) is a major problem both in India and worldwide. Newer drugs such as TMC-207 (bedaquiline) may have an important role to play in making up…

Continue ReadingInitial experience of bedaquiline use in a series of drug-resistant tuberculosis patients from India.
  • Post author:plus91
  • Post published:October 30, 2014
  • Post category:Publication
  • Post comments:0 Comments

AbstractBACKGROUND:There is very limited data on the experience and outcome of multidrug-resistant tuberculosis (MDR-TB) patients treated privately out of the DOTS plus program. Goal of this study is…

Continue ReadingMultidrug-resistant-tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai.
  • Post author:plus91
  • Post published:July 17, 2014
  • Post category:Publication
  • Post comments:0 Comments

Go to Publication

Continue Reading“Chennai Declaration”: 5-year plan to tackle the challenge of anti-microbial resistance.
  • Post author:plus91
  • Post published:May 18, 2014
  • Post category:Publication
  • Post comments:0 Comments

AbstractBACKGROUND:Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice…

Continue ReadingEfficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
  • Post author:plus91
  • Post published:April 20, 2014
  • Post category:Publication
  • Post comments:0 Comments

AbstractExtensively drug-resistant tuberculosis is a burgeoning global health crisis mainly affecting economically active young adults, and has high mortality irrespective of HIV status. In some countries such as…

Continue ReadingGlobal control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis.
  • Go to the previous page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 17
  • Go to the next page

Hinduja Hospital,

Mahim, Mumbai – 400016

Appointment –
022 45108181, 022 67668181

Office – 022 24447353

Breach Candy Hospital,

B. Desai Road, Mumbai – 400026

Appointment – 5-8 pm
022 23667900
022 23667995

 

Thomas Cook Building,

DN Road, Mumbai – 400001

Appointment – After 6 pm
022 22046210
022 67439337

Copyright 2026 - Dr.Zarir Udwadia